Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 101 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 101 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
95(94.1%)
Phase 1
5(5.0%)
Phase 2
1(1.0%)
101Total
N/A(95)
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (101)

Showing 20 of 101 trials
NCT02327247Not ApplicableCompleted

Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions

Role: lead

NCT02312297Not ApplicableCompleted

Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions

Role: lead

NCT02312609Not ApplicableCompleted

Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fed Conditions

Role: lead

NCT02311530Not ApplicableCompleted

Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions

Role: lead

NCT02306889Not ApplicableCompleted

Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions

Role: lead

NCT02306902Not ApplicableCompleted

Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions

Role: lead

NCT02197494Not ApplicableCompleted

Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions

Role: lead

NCT02197442Not ApplicableCompleted

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Role: lead

NCT01654718Not ApplicableCompleted

Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study

Role: lead

NCT01654705Not ApplicableCompleted

Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study

Role: lead

NCT01276067Phase 1Completed

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

Role: lead

NCT01499771Phase 1Completed

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

Role: lead

NCT01276080Phase 1Completed

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions

Role: lead

NCT01499758Phase 1Completed

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.

Role: lead

NCT01523080Not ApplicableCompleted

A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fasting Condition

Role: lead

NCT01523119Not ApplicableCompleted

Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions

Role: lead

NCT01523093Not ApplicableCompleted

Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions

Role: lead

NCT01513668Not ApplicableCompleted

A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fed Condition

Role: lead

NCT01222975Not ApplicableCompleted

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions

Role: lead

NCT01222897Not ApplicableCompleted

A Relative Bioavailability Study of Valacyclovir Hydrochloride Tablets 1gm Under Fed Condition

Role: lead